Kritikou, Persefoni

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER 2‐positive early breast cancer

De Cock, E., Pivot, X., Hauser, N., Verma, S., Kritikou, P., Millar, D., & Knoop, A. (2016) · Cancer Medicine

HER2/EGFR in Cancer ResearchHealth Systems, Economic Evaluations, Quality of Life

Cited by 112

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries

De Cock, E., Kritikou, P., Sandoval, M., Tao, S., Wiesner, C., Carella, A. M., Ngoh, C., & Waterboer, T. (2016) · PLOS ONE

Lymphoma Diagnosis and TreatmentHealthcare Operations and Scheduling Optimization

Cited by 108

An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries

Body, J.-J., Gatta, F., De Cock, E., Tao, S., Kritikou, P., Wimberger, P., Mebis, J., Peeters, M., Pedrazzoli, P., Caraceni, A., et al. (2017) · Supportive Care in Cancer

Bone health and treatmentsBone health and osteoporosis research

Cited by 11

Time Savings With Rituximab Subcutaneous (SC) Injection Vs Rituximab Intravenous (IV) Infusion: Final Analysis From a Time-and-Motion Study In 8 Countries

De Cock, E., Kritikou, P., Tao, S., Wiesner, C., Waterboer, T., & Carella, A. M. (2013) · Blood

Lymphoma Diagnosis and TreatmentHealth Systems, Economic Evaluations, Quality of Life

Cited by 7